Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Genome-wide ctDNA assessment predicts outcome and resistance in HR+/HER2- MBC treated with CDK4/6i

The use of CDK4/6 inhibitors in combination with endocrine therapy improves survival in patients with hormone receptor-positive, HER2-negative metastatic breast cancer however further response biomarkers are required. In this interview, Andrew A. Davis, MD, Washington University School of Medicine, St. Louis, MO, discusses the development of a comprehensive next-generation sequencing (NGS)-based liquid biopsy assessment of ctDNA mutation and copy number analysis which can be used to identify novel prognostic and predictive biomarkers. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.